All articles by Staff Writer
Staff Writer
Lupin Launches Propranolol Long-Acting Capsules to Improve Heart Health in Canada.
Lupin Pharma Canada Ltd., a wholly-owned subsidiary of Lupin Limited (Lupin), today announced the launch of Propranolol LA (long-acting) capsules,60 mg, 80 mg, 120 mg and 160 mg, in Canada. Propranolol LA is a generic equivalent of Inderal® LA, it provides an effective treatment solution since the discontinuation of Inderal® LA for patients and healthcare practitioners. Propranolol LA’s launch caters to the needs of Canadian patients,reaffirming Lupin’s commitment to enhancing healthcare access and affordability.
Navigating the Future of Neurosurgery: Brain Navi demonstrates NaoTrac and KrystoLens at CNS 2023 & EANS 2023
Brain Navi announced today the demonstration of NaoTrac, a neurosurgical navigation robot and KrystoLens, a single-use neuro-endoscope at CNS 2023 in Washington D.C. and EANS 2023 in Barcelona, respectively.
Mindray Introduces Innovative Upgrades to A Series Anaesthesia Systems for Enhanced Patient Safety and Efficiency
Mindray (SZSE: 300760), a global leader in providing advanced medical device solutions, has unveiled upgrades to its A7 and A5 anaesthesia systems under the A Series Anaesthesia. These enhancements incorporate innovative technologies that empower anaesthesiologists to deliver precise anaesthesia, leading to greater patient safety and efficiency throughout the perioperative period.
Novo Nordisk acquires Embark Biotech, including its lead asset targeting obesity and other cardiometabolic diseases.
Embark Laboratories announced today that Novo Nordisk has acquired Embark Biotech, including its lead metabolic program, and has entered a three-year research and development collaboration to discover and develop novel pharmaceuticals to treat obesity and related co-morbidities.
Casio to Release Uterocervical Observation Camera and Camera Stand in Europe
Completion of the Declarations of Conformity to European Medical Device Regulations (EU MDR) and UK Medical Device Regulations (UK MDR)
Leslie McDonnell joins Mölnlycke’s Board of Directors
Leslie McDonnell has been elected Member of Mölnlycke AB’s Board of Directors on 1 September 2023.
Baltimore VA Medical Centre opts for CareView patient monitoring tech
This system provides real-time insights to healthcare providers for predicting inpatient falls.
Roche’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III ALINA study evaluating Alecensa® (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS) at a prespecified interim analysis. Alecensa demonstrated a statistically significant and clinically meaningful improvement in DFS as adjuvant therapy in people with completely resected stage IB (tumour ≥4cm) to IIIA (UICC/AJCC 7th edition) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Alecensa is the first and only ALK inhibitor to demonstrate a reduction in the risk of disease recurrence or death for people with early-stage ALK-positive NSCLC in a Phase III trial.
Healthcare companies using Google Cloud generative AI tools
Huma said it expects the technology to automate its clinical summary reports and improve its data triaging processes.
Start-up Time is Brain monitors brain function after stroke
Interview with Alicia Martínez (PhD), CEO, Time is Brain